Core Insights - The article highlights the interconnection between overweight/obesity and emotional issues, emphasizing the need for effective solutions to address both health concerns [1][3]. Group 1: Health Impact - Research indicates that among individuals with Metabolic Associated Fatty Liver Disease (MAFLD), the prevalence of depressive symptoms is as high as 63.8%, while anxiety symptoms are detected in 36.2% of the population [1]. - The Akk11 strain of Akkermansia muciniphila, developed by Weikang Probiotics, has shown significant benefits in improving emotional states and reducing depression scores as measured by the PHQ-9 scale [3]. Group 2: Mechanism of Action - Akk11 operates through the "gut-brain axis," influencing neurotransmitter and hormone pathways, thereby positively affecting metabolic functions and emotional states [5]. - The strain promotes the secretion of key satiety hormones GLP-1 and PYY, which help suppress appetite and improve metabolic levels [3][5]. Group 3: Production and Efficacy - Weikang Probiotics has achieved large-scale production of Akk11, with an annual capacity of 200 tons, ensuring a stable supply of high-activity products [5]. - The active products contain 600 billion AFU per gram, while inactivated products reach up to 10 trillion TFU per gram, providing robust support for weight management health products [5]. Group 4: Scientific Validation - Akk11's safety and efficacy have been validated through five clinical studies, five SCI papers, and over ten patents, along with international GRAS safety certification [1][5]. - The clinical study (NCT06653101) specifically assesses Akk11's impact on improving body fat, metabolic levels, and emotional health in overweight individuals [5].